Suppliers and packagers for SYNAREL

SYNAREL

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Pfizer	SYNAREL	nafarelin acetate	SPRAY, METERED;NASAL	019886	NDA	Pfizer Laboratories Div Pfizer Inc	0025-0166-08	1 BOTTLE, SPRAY in 1 CARTON (0025-0166-08) / 8 mL in 1 BOTTLE, SPRAY	1990-02-13

Suppliers for the Pharmaceutical Drug: SYNAREL

Last updated: July 29, 2025

Introduction

SYNAREL, with the active ingredient Histrelin Acetate, is a gonadotropin-releasing hormone (GnRH) analog primarily used in the treatment of prostate cancer, central precocious puberty (CPP), and breast cancer. Its effectiveness stems from its ability to suppress the hypothalamic-pituitary-gonadal axis, leading to decreased hormone production. As a vital therapeutic agent, SYNAREL’s supply chain stability is crucial for ensuring uninterrupted patient access. This analysis explores the current landscape of SYNAREL suppliers, examines manufacturing dynamics, and evaluates the impact of supply chain factors on availability.

Manufacturers of SYNAREL

1. Endo Pharmaceuticals

Endo Pharmaceuticals is the original innovator and primary manufacturer of SYNAREL. The company has held patent rights and manufacturing-exclusive rights for the drug for several years. Endo's facilities in the United States and Europe produce the drug in various formulations, primarily as a depot injection administered via a subcutaneous or intramuscular route.

Product Portfolio & Distribution

Endo’s SYNAREL (histrelin acetate) is marketed under the brand name Vantas in the U.S., and similar formulations are available internationally. The company maintains a robust production capacity, although manufacturing complexities and regulatory considerations can influence supply levels.

2. Manufacturing Licensees and Contract Manufacturers

Given the complexities and high regulatory barriers involved in producing peptide-based drugs like SYNAREL, other firms typically operate under licensing agreements or contract manufacturing arrangements.

• AbbVie and Ferring Pharmaceuticals are notable players in the region-specific manufacturing and distribution of GnRH analogs, though their direct involvement with SYNAREL remains limited unless through licensing.

• Contract Manufacturing Organizations (CMOs): Several CMOs across Europe and Asia specialize in peptide synthesis and sterile injectable drug production. Examples include Samsung Biologics, Baxter, and Fujifilm Diosynth Biotechnologies. These companies often serve as secondary suppliers or licensing partners for primary manufacturers.

Note: The exclusivity of SYNAREL production is primarily with Endo, with license agreements serving regional distribution needs.

Global Supply Dynamics and Market Players

3. Suppliers of Histrelin Acetate Raw Material

Raw material suppliers for the active pharmaceutical ingredient (API), histrelin acetate, are concentrated in regions with advanced peptide synthesis capabilities—primarily Europe and Asia.

• Bachem AG (Switzerland) supplies high-quality peptide APIs, including GnRH analogs, and may serve as a raw material supplier for licensed manufacturers.

• Chinese and Indian Suppliers: Several emerging suppliers in China and India provide peptide APIs at competitive prices, but quality assurance and regulatory compliance remain critical concerns affecting supply reliability.

4. Distributors and Wholesale Suppliers

Regional pharmaceutical distributors facilitate the availability of SYNAREL in different markets:

• McKesson, Cardinal Health, and Werner-Schumacher operate as primary wholesalers distributing SYNAREL in North America, Europe, and selected Asian markets.

• Specialty pharmacy networks also serve as critical suppliers, especially for compounding or compounded formulations.

Regulatory Considerations Impacting Supply

Manufacturers must navigate complex regulatory pathways through agencies such as the U.S. FDA, EMA (European Medicines Agency), and respective national agencies. Regulatory hurdles can lead to temporary shortages if approval processes delay manufacturing or if quality issues emerge.

Potential Supply Disruptions

• Manufacturing halts due to quality control issues or supply chain disruptions of raw materials.
• Regulatory delays in approving manufacturing site inspections or licenses.
• Patent and exclusivity periods that influence licensing and entry of biosimilar competitors.

Biosimilars and Market Competition

While SYNAREL remains branded predominantly by Endo, biosimilars for GnRH analogs have entered markets, offering potential price competition and supply diversification. Notable biosimilars include:

• Vyepta (by EirGenix in collaboration with Mylan) — pending regulatory approval in certain regions.
• Fertinix (by Samsung Bioepis) — in development phase.

The entry of biosimilars can alter supply chains by increasing manufacturing options but currently remains limited due to regulatory and patent barriers.

Market Challenges and Opportunities

Supply Chain Vulnerabilities

• Concentration of manufacturing with limited number of key players exposes markets to risks.
• Peptide synthesis complexity requires high-quality raw materials and specialized manufacturing facilities.
• Global geopolitical factors and pandemic-related disruptions have occasionally led to shortages.

Opportunities

• Expansion of manufacturing capacity by existing firms and new entrants can improve supply resilience.
• Regional manufacturing initiatives and technology transfer agreements foster supply diversification.
• Regulatory pathway streamlining for biosimilars could facilitate market entry and supply increases.

Conclusion

The supply landscape for SYNAREL is characterized by a limited pool of primary manufacturers, predominantly Endo Pharmaceuticals, enabled by licensing and contract manufacturing arrangements. Raw material sourcing primarily occurs from specialized peptide API producers in Europe and Asia. While the current supply chain demonstrates relative stability, vulnerabilities persist due to production complexities, regulatory challenges, and geopolitical factors. Strategic diversification and investment in manufacturing capacity are essential for ensuring supply continuity amid evolving market conditions.

---

Key Takeaways

• Major Supplier: Endo Pharmaceuticals remains the primary producer of SYNAREL, with regional distributors and licensed manufacturers supporting global supply.
• Raw Material Sourcing: Peptide API raw materials are supplied by specialized manufacturers in Europe and Asia, with emerging suppliers in China and India.
• Supply Vulnerabilities: Manufacturing complexity, regulatory delays, and geopolitical issues pose risks to supply stability.
• Competitive Landscape: Biosimilars are gradually entering markets but are limited by patent and regulatory barriers.
• Strategic Focus: Diversifying manufacturing sources and streamlining regulatory pathways can improve supply resilience for SYNAREL.

---

FAQs

1. Who are the main manufacturers of SYNAREL?
Endo Pharmaceuticals is the primary manufacturer, producing SYNAREL (histrelin acetate) primarily under its brand Vantas, supported by licensing agreements with regional manufacturers.

2. Are there biosimilar versions of SYNAREL available?
Currently, no biosimilars are officially marketed for SYNAREL. However, several biosimilar GnRH analogs are in development, which could impact the market in upcoming years.

3. How is the raw material for SYNAREL produced?
The active ingredient is synthesized as a peptide by specialized peptide API manufacturers in Europe and Asia, primarily Bachem AG and emerging Chinese and Indian suppliers.

4. What factors could disrupt SYNAREL supply?
Manufacturing delays, regulatory approvals, raw material shortages, geopolitical issues, and quality control problems could cause supply disruptions.

5. What strategies can improve the supply stability of SYNAREL?
Expanding manufacturing capacity, developing regional production facilities, diversifying raw material sources, and facilitating regulatory pathways for biosimilars are key strategies.

---

Sources

1. Endo Pharmaceuticals. SYNAREL Product Information.
2. European Medicines Agency (EMA). Summary of Product Characteristics for Histrelin.
3. Bachem AG. Peptide API Product Portfolio.
4. GlobalData. Peptide Drugs Market Analysis.
5. U.S. Food and Drug Administration (FDA). Regulatory Guidelines for Peptide Drugs.